线粒体融合是急性髓系白血病的治疗脆弱性
该研究在患者来源的异种移植(PDX)模型中显示,靶向线粒体融合是急性髓系白血病(AML)细胞的新脆弱性。遗传敲低MFN2或OPA1、或药物抑制OPA1(MYLS22)可阻断线粒体融合,具有显著抗白血病活性,而对正常造血细胞影响有限。机制上,抑制线粒体融合破坏线粒体呼吸和活性氧产生,导致细胞周期阻滞于G0/G1转换。
要点
- 在PDX模型中,靶向线粒体融合对AML细胞具有抗白血病活性。
- 遗传敲低MFN2或OPA1、或药物抑制OPA1(MYLS22)可阻断线粒体融合。
- 抑制线粒体融合对正常造血细胞影响有限。
核心结论
- 抑制线粒体融合被提名为AML有前景的治疗方法。
研究设计与样本
- 研究在患者来源的异种移植(PDX)模型中进行。
主要发现
- 遗传敲低MFN2或OPA1、或药物抑制OPA1(MYLS22)阻断线粒体融合,具有显著抗白血病活性,而对正常造血细胞在体外和体内影响有限。
- 抑制线粒体融合破坏线粒体呼吸和活性氧产生,导致细胞周期阻滞于G0/G1转换。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mitochondrial metabolism recently emerged as a critical dependency in acute myeloid leukemia (AML). The shape of mitochondria is tightly regulated by dynamin GTPase proteins, which drive opposing fusion and fission forces to consistently adapt bioenergetics to the cellular context. Here, we showed that targeting mitochondrial fusion was a new vulnerability of AML cells, when assayed in patient-derived xenograft (PDX) models. Genetic depletion of mitofusin 2 (MFN2) or optic atrophy 1 (OPA1) or pharmacological inhibition of OPA1 (MYLS22) blocked mitochondrial fusion and had significant anti-leukemic activity, while having limited impact on normal hematopoietic cells ex vivo and in vivo. Mechanistically, inhibition of mitochondrial fusion disrupted mitochondrial respiration and reactive oxygen species production, leading to cell cycle arrest at the G0/G1 transition. These results nominate the inhibition of mitochondrial fusion as a promising therapeutic approach for AML.
引用
- Larrue C, Mouche S, Lin S, et al. Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia. Leukemia. 2023. PMID: 36739349. doi:10.1038/s41375-023-01835-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。